<p>MiNK Therapeutics（纳斯达克代码：INKT - 获取免费报告）于周五公布了季度财报。该公司报告每股收益（EPS）为（$0.65），超出市场共识预期的（$0.86）$0.21，Zacks 报道。</p>
<p>获取 <strong>MiNK Therapeutics</strong> 的提醒：</p>
<h2>MiNK Therapeutics 股票表现</h2>
<p>周五午盘交易中，INKT 股票下跌 $0.47，达到 $12.75。该公司交易了 19,480 股，较其平均交易量 20,730 股有所减少。公司的 50 日移动平均价格为 $14.33，200 日移动平均价格为 $12.81。该公司的市值为 5865 万美元，市盈率为 -4.43，贝塔值为 0.33。MiNK Therapeutics 的 12 个月低点为 $4.56，12 个月高点为 $76.00。</p>
<h2>华尔街分析师观点</h2>
<p>多家股票研究分析师对 INKT 股票发布了报告。华尔街 Zen 在 8 月 23 日的研究报告中将 MiNK Therapeutics 的评级下调至 “强烈卖出”。Zacks Research 在 10 月 20 日的报告中将 MiNK Therapeutics 的评级从 “强烈卖出” 上调至 “持有”。B. Riley 在 7 月 18 日的研究报告中将 MiNK Therapeutics 的评级上调至 “强烈买入”。HC Wainwright 在 8 月 15 日的研究报告中将 MiNK Therapeutics 的评级从 “中性” 上调至 “买入”，并设定了 $35.00 的目标价。最后，Weiss Ratings 在 10 月 8 日的报告中重申了 MiNK Therapeutics 的 “卖出（d-）” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，两位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 $37.50。</p>
<p><strong>查看我们对 MiNK Therapeutics 的最新分析</strong></p>
<h2>MiNK Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>MiNK Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于发现、开发和商业化同种异体、现成的、不变的自然杀伤 T（iNKT）细胞疗法，以治疗癌症和其他免疫介导的疾病。其产品候选药物为 AGENT-797，一种现成的同种异体 iNKT 细胞疗法，用于治疗各种骨髓瘤疾病和实体肿瘤，目前处于 1 期临床试验阶段。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，而不是 MiNK Therapeutics</li>
<li>大型股的定义及如何投资</li>
<li>这三只被低估的科技巨头准备反弹吗？</li>
<li>三只股票保护您的投资组合免受冠状病毒影响</li>
<li>如果您等待下跌，Micron Technology 可能会让您错失良机</li>
<li>为什么股票行业对成功投资至关重要？</li>
<li>三只悄然推动 AI 和科技革命的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5LVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5LVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 MiNK Therapeutics 吗？</h2>
<p>在考虑 MiNK Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 MiNK Therapeutics 并不在名单上。</p>
<p>虽然 MiNK Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

INKT

<p>MiNK Therapeutics 公布了季度财报，每股收益为（$0.65），超出市场共识预期的（$0.86）$0.21。尽管如此，股价下跌$0.47，至$12.75。分析师的评级不一，从 “强烈卖出” 到 “强烈买入” 都有，市场共识为 “适度买入”，目标价为$37.50。该公司专注于针对癌症和免疫疾病的 iNKT 细胞疗法，其产品 AGENT-797 正在进行第一阶段临床试验</p>

<p>MiNK Therapeutics (NASDAQ:INKT - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.21, Zacks reports.</p>
<div class="lb-trans"><p>MiNK Therapeutics（纳斯达克代码：INKT - 获取免费报告）于周五公布了季度财报。该公司报告每股收益（EPS）为（$0.65），超出市场共识预期的（$0.86）$0.21，Zacks 报道。</p>
</div><p>Get <strong>MiNK Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>MiNK Therapeutics</strong> 的提醒：</p>
</div><h2>MiNK Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>MiNK Therapeutics 股票表现</h2>
</div><p>Shares of INKT stock traded down $0.47 during midday trading on Friday, reaching $12.75. 19,480 shares of the company were exchanged, compared to its average volume of 20,730. The company's 50 day moving average price is $14.33 and its two-hundred day moving average price is $12.81. The company has a market cap of $58.65 million, a P/E ratio of -4.43 and a beta of 0.33. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00.</p>
<div class="lb-trans"><p>周五午盘交易中，INKT 股票下跌 $0.47，达到 $12.75。该公司交易了 19,480 股，较其平均交易量 20,730 股有所减少。公司的 50 日移动平均价格为 $14.33，200 日移动平均价格为 $12.81。该公司的市值为 5865 万美元，市盈率为 -4.43，贝塔值为 0.33。MiNK Therapeutics 的 12 个月低点为 $4.56，12 个月高点为 $76.00。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities research analysts have issued reports on INKT shares. Wall Street Zen cut MiNK Therapeutics to a &#34;strong sell&#34; rating in a research note on Saturday, August 23rd. Zacks Research raised shares of MiNK Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 20th. B. Riley raised shares of MiNK Therapeutics to a &#34;strong-buy&#34; rating in a research note on Friday, July 18th. HC Wainwright upgraded shares of MiNK Therapeutics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $35.00 price target on the stock in a research note on Friday, August 15th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of MiNK Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $37.50.</p>
<div class="lb-trans"><p>多家股票研究分析师对 INKT 股票发布了报告。华尔街 Zen 在 8 月 23 日的研究报告中将 MiNK Therapeutics 的评级下调至 “强烈卖出”。Zacks Research 在 10 月 20 日的报告中将 MiNK Therapeutics 的评级从 “强烈卖出” 上调至 “持有”。B. Riley 在 7 月 18 日的研究报告中将 MiNK Therapeutics 的评级上调至 “强烈买入”。HC Wainwright 在 8 月 15 日的研究报告中将 MiNK Therapeutics 的评级从 “中性” 上调至 “买入”，并设定了 $35.00 的目标价。最后，Weiss Ratings 在 10 月 8 日的报告中重申了 MiNK Therapeutics 的 “卖出（d-）” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，两位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 $37.50。</p>
</div><p><strong>Check Out Our Latest Analysis on MiNK Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MiNK Therapeutics 的最新分析</strong></p>
</div><h2>MiNK Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>MiNK Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.</p>
<div class="lb-trans"><p>MiNK Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于发现、开发和商业化同种异体、现成的、不变的自然杀伤 T（iNKT）细胞疗法，以治疗癌症和其他免疫介导的疾病。其产品候选药物为 AGENT-797，一种现成的同种异体 iNKT 细胞疗法，用于治疗各种骨髓瘤疾病和实体肿瘤，目前处于 1 期临床试验阶段。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than MiNK Therapeutics</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>3 Stocks Quietly Powering the AI and Tech Revolution</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 MiNK Therapeutics</li>
<li>大型股的定义及如何投资</li>
<li>这三只被低估的科技巨头准备反弹吗？</li>
<li>三只股票保护您的投资组合免受冠状病毒影响</li>
<li>如果您等待下跌，Micron Technology 可能会让您错失良机</li>
<li>为什么股票行业对成功投资至关重要？</li>
<li>三只悄然推动 AI 和科技革命的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5LVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=INKT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiNK Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 MiNK Therapeutics 吗？</h2>
</div><p>Before you consider MiNK Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MiNK Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiNK Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 MiNK Therapeutics 并不在名单上。</p>
</div><p>While MiNK Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MiNK Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MiNK Therapeutics（纳斯达克代码：INKT）公布了财报，每股收益比预期高出 0.21 美元